Cargando…

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

OBJECTIVE: Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention. The aim of this research was to quan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hare, Kristine J., Vilsbøll, Tina, Asmar, Meena, Deacon, Carolyn F., Knop, Filip K., Holst, Jens J.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Pathophysiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889777/ https://www.ncbi.nlm.nih.gov/pubmed/20150286 http://dx.doi.org/10.2337/db09-1414

Ejemplares similares

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes
por: Menge, Björn A., et al.
Publicado: (2011)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
por: Nauck, Michael A., et al.
Publicado: (2011)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Searching for the physiological role of glucose‐dependent insulinotropic polypeptide
por: Holst, Jens Juul, et al.
Publicado: (2016)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis
por: Picha, Kristen M., et al.
Publicado: (2008)

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism
por: Chai, Weidong, et al.
Publicado: (2012)

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
por: Asmar, Meena, et al.
Publicado: (2010)

Natural History of Insulin Sensitivity and Insulin Secretion in the Progression From Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance: The Inter99 Study
por: Færch, Kristine, et al.
Publicado: (2009)

Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus
por: Yeow, Toh Peng, et al.
Publicado: (2017)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin’s Metabolic Action in the Presence of Insulin Resistance
por: Chai, Weidong, et al.
Publicado: (2014)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction
por: Sassoon, Daniel J., et al.
Publicado: (2017)

Na(+)-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
por: Gorboulev, Valentin, et al.
Publicado: (2012)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty
por: Plamboeck, Astrid, et al.
Publicado: (2013)

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
por: Kanat, Mustafa, et al.
Publicado: (2012)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss
por: Asmar, M, et al.
Publicado: (2016)

Intergenerational Transmission of Glucose Intolerance and Obesity by In Utero Undernutrition in Mice
por: Jimenez-Chillaron, Josep C., et al.
Publicado: (2009)

Hypothalamic Vitamin D Improves Glucose Homeostasis and Reduces Weight
por: Sisley, Stephanie R., et al.
Publicado: (2016)

Impaired Glucose Tolerance in the Absence of Adenosine A1 Receptor Signaling
por: Faulhaber-Walter, Robert, et al.
Publicado: (2011)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

Postprandial and Fasting Hepatic Glucose Fluxes in Long-Standing Type 1 Diabetes
por: Kacerovsky, Michaela, et al.
Publicado: (2011)

Brain Insulin Action Regulates Hypothalamic Glucose Sensing and the Counterregulatory Response to Hypoglycemia
por: Diggs-Andrews, Kelly A., et al.
Publicado: (2010)

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
por: Jurczak, Michael J., et al.
Publicado: (2011)

Small Decrements in Systemic Glucose Provoke Increases in Hypothalamic Blood Flow Prior to the Release of Counterregulatory Hormones
por: Page, Kathleen A., et al.
Publicado: (2009)

Short-Term Caloric Restriction Normalizes Hypothalamic Neuronal Responsiveness to Glucose Ingestion in Patients With Type 2 Diabetes
por: Teeuwisse, Wouter M., et al.
Publicado: (2012)

Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet–Induced Insulin Resistance
por: Zhang, Wei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vbs2781uiv1l9p3ccm22d1ca6t